Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice by Kobayashi, Toshihiko et al.
International Immunology, Vol. 20, No. 7, pp. 881–891
doi:10.1093/intimm/dxn049
ª The Japanese Society for Immunology. 2008. All rights reserved.
For permissions, please e-mail: journals.permissions@oxfordjournals.org
Tonic B cell activation by Radioprotective105/MD-1
promotes disease progression in MRL/lpr mice
Toshihiko Kobayashi1,2, Koichiro Takahashi1, Yoshinori Nagai1,6, Takuma Shibata1,
Masako Otani3, Shozo Izui3, Shizuo Akira4, Yoshiyuki Gotoh5, Hiroshi Kiyono5 and
Kensuke Miyake1
1Division of Infectious Genetics, Institute of Medical Science, University of Tokyo, Tokyo, Japan
2Japan Society for the Promotion of Science, Tokyo, Japan
3Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
4Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
5Division of Mucosal Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
6Present address: Department of Immunobiology and Pharmacological Genetics, Graduate School of Medicine and
Pharmaceutical Science for Research, University of Toyama, Toyama, Japan
Keywords: autoimmunity, B cells, innate immunity
Abstract
Toll-like receptors (TLRs) have a crucial role in sensing microbial products and triggering immune
responses. Recent reports have indicated that TLR7 and TLR9 have an important role in activating
autoreactive B cells. In addition to TLR7 and TLR9, mouse B cells express TLR2, TLR4 and
structurally related Radioprotective105 (RP105). We have previously shown that RP105 works in
concert with TLR2/4 in antibody response to TLR2/4 ligands. We here report that B cells are
constitutively activated by TLR2/4 and RP105. Such B cell activation was revealed by the g3 germ line
transcript and serum IgG3 production, both of which were impaired by the lack of RP105 or TLR2/4.
Serum IgG3 was not altered in germ-free or antibiotics-treated mice, suggesting that the microbial
flora hardly contributes to the continuous activation of B cells. The lack of RP105-dependent B cell
activation ameliorated disease progression in lupus-prone MRL/lpr mice. RP1052/2 MRL/lpr mice
showed less lymphoadenopathy/splenomegaly and longer survival than MRL/lpr mice. Whereas
glomerulonephritis and auto-antibody production were not altered, improvement in blood urea
nitrogen and lower incidence of renal arteritis indicated that renal function was ameliorated in the
absence of RP105. Our results suggest that RP105-dependent tonic B cell activation has a pathogenic
role in MRL/lpr mice.
Introduction
Systemic lupus erythematosus (SLE) is multisystem, autoim-
mune, connective tissue disorder with a broad range of clini-
cal features. Pathogenic mechanisms underlying SLE are
largely unknown. Mouse models of SLE have provided sig-
nificant insights into the identification of critical molecular
pathways that mediate the generation of this autoimmune
disease. Two mouse strains have been extensively studied.
The NZB/NZW F1 (BWF1) lupus nephritis model shares
pathogenic features with human SLE (1). The other strain,
MRL/lpr, is also a well-established murine model of SLE, in
which the disease is characterized by glomerulonephritis
with immune complex deposition, vasculitis, splenomegaly,
lymphadenopathy and auto-antibody production (2).
Auto-antibody is a general feature of lupus, and the mech-
anisms that result in the selection and expansion of auto-
antibody-producing B cells have been suggested to involve
the Toll-like receptors (TLRs) (3). TLRs are known to recog-
nize microbial molecules ranging from nucleic acids to mem-
brane lipids. These receptors can activate diverse cell
populations of the immune system to initiate or enhance
protective immune responses. On a susceptible genetic
background, however, TLR signaling also induces autoim-
munity. In particular, TLR7 and TLR9 can provide a co-
stimulatory signal for auto-antibody production (4, 5). The
lack of TLR7 or TLR9 down-regulated auto-antibody produc-
tion in autoimmune-prone mice (5).
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In addition to nucleic acid-sensing TLRs, mouse B cells
express TLR2 and TLR4/MD-2, both of which were reported
to respond to microbial membrane components and non-
microbial products derived from tissue damages (6–11).
B cells also express Radioprotective105 (RP105)/MD-1,
which is structurally and functionally related to the LPS sen-
sor TLR4/MD-2 (12–15). RP105 forms a complex with MD-1
and can transmit strong proliferation signals into B cells
when ligated by a specific mAb. Although RP105/MD-1 is
expressed on dendritic cells and macrophages as well,
TLR2/4 responses were impaired only in B cells (16).
RP105/MD-1 was reported to be associated with TLR4/MD-2
(17), suggesting that RP105/MD-1 is activated simulta-
neously with TLR4 by co-clustering. RP105/ mice were as
low as myeloid differentiation gene 88 (MyD88/) mice in
serum IgG3 production. Little is known about roles for
RP105/MD-1 in autoimmune diseases. We here studied roles
for RP105 in B cell activation in the steady state and in auto-
immune diseases in MRL/lpr and BWF1 mice. The present
study demonstrated that RP105/MD-1 works in concert
with TLR2/TLR4 in constitutive B cell activation in the steady
state and has a pathogenic role in autoimmune diseases in
MRL/lpr mice but not in BWF1 mice. Taken together, tonic
B cell activation by the cell surface complex consisting of
TLR2, TLR4 and RP105/MD-1 may have a pathogenic role
in MRL/lpr mice.
Methods
Mice
C57BL/6 mice were purchased from Japan SLC co.
(Shizuoka, Japan) and used for analyses at 7–12 weeks of
age. Mutant mice were maintained in the animal facility at
the Institute of Medical Science, the University of Tokyo.
C57BL/6 RP105/, MD-1/ mice have been described
previously (14, 18). MyD88/, TRIF/, TIRAP/ and
TLR7/ or TLR7/y mice were provided by S. Akira (Osaka
University). RP105/ autoimmune mice were generated by
intercrossing C57BL/6 RP105/ mice with MRL/MpJlpr/lpr
mice. After ninth backcross generation, mice were analyzed
at 19–20 weeks of age. RP105/ New Zealand Black (NZB)
and RP105/ New Zealand White (NZW) mice were gener-
ated by intercrossing C57BL/6 RP105/ mice with NZB or
NZW mice. After backcrossing 10 generations, RP105+/ or
RP105/ NZB/W F1 (BWF1) mice were generated by
breeding NZB RP105+/ and NZW RP105/ mice.
Germ-free mice at 7 weeks of age (ICR mice) and their
control-specific pathogen-free mice were purchased from
CLEA Japan. Germ-free mice were maintained in the sterile
condition from their birth and fed with sterilized chow.
Germ-free mice were confirmed by the absence of bacterial
colony in feces. For antibiotics treatment, mice were fed with
drinking water containing ampicillin 1 g l1, neomycin 1 g l1,
vancomycin 0.5 g l1 and metronidazole 0.5 g l1 during
4–8 weeks of age. Unless otherwise noted, female mice
were used for all experiments in this study. All the animal
experiments were conducted with the approval of the Animal
Research Committee at the Institute of Medical Science in
the University of Tokyo.
Reagents
LPS from Escherichia coli (serotype O55:B5) was purchased
from Sigma–Aldrich (St Louis, MO, USA). N-palmitoyl-S-(2,3-
bis (palmitoyloxy)-(2R,S)-propyl)-(R)-cysteinyl-seryl-(lysyl)3-
lysine (P3CSK4) was purchased from EMC microcollections
(Tubingen, Germany). CpG (CpG1668: TCCATGACGTTCCT-
GATGCT) was purchased from Hokkaido System Science
(Sapporo, Japan). Loxoribine (7-allyl-8-oxo-guanosine) and
poly(I:C) were purchased from InvivoGen (San Diego, CA,
USA). Lymphocytes from 19-week-old mice were stained
with the following antibodies: FITC-anti-CD4, PE-anti-CD8
and PE-Cy7-anti-CD3e for T cell separation; PE-Cy7-anti-
CD19 for B cell separation; FITC-anti-CD44 and biotinylated
anti-CD69 followed by allophycocyanin–streptavidin for the
analysis of lymphocyte activation status, respectively. Stained
cells were analyzed by flow cytometry (BD FACSCalibur; BD
Biosciences).
Measurement of serum Ig titer
The levels of serum Igs were measured by ELISA as de-
scribed previously (16). Briefly, goat anti-mouse Ig (H+L) an-
tibody (SouthernBiotech, Birmingham, AL, USA) was coated
onto the ELISA plate and blocked with 0.5% BSA, and serial
serum dilutions were applied. Bound antibodies were
detected by peroxidase-conjugated goat antibodies to
IgG1, IgG2a, IgG2b, IgG2c (for C57BL/6 mice), IgG3, IgM
or IgA.
Auto-antibody measurement
Serum levels of IgG auto-antibodies against chromatin and
double-stranded DNA (dsDNA) were determined by ELISA
as described previously (19, 20). The assay was developed
with alkaline phosphatase-conjugated anti-mouse IgM,
IgG1, IgG2a, IgG2b and IgG3 antibodies (SouthernBiotech).
For the measurement of anti-IgG2a rheumatoid factor (RF),
ELISA plates were coated with 2,4-dinitrophenyl (DNP)–
BSA and then incubated with IgG2a anti-DNP (Hy1.2) mAb
as a competitor against anti-DNA antibodies (21). These
plates were then incubated with two different dilutions of
sera (1:200 and 1:1000), and the assay was developed with
alkaline phosphatase-conjugated anti-mouse IgG3.
Blood urea nitrogen
Amount of blood urea nitrogen (BUN) in mice sera was mea-
sured by using BUN-kainos kit (Kainos Inc., Tokyo, Japan),
according to the manufacturer’s instruction.
Quantitative reverse transcription–PCR
Splenic B cells from non-immune mice were separated by
CD43 negative selection using AutoMACS system (Miltenyi
Biotec). B cell purity was >95%, as judged by flow cytome-
try analyses. Total RNA was extracted from splenic B cells
using RNeasy kit (QIAGEN) and cDNA was synthesized with
SuperScript III First-Strand cDNA Synthesis System for re-
verse transcription–PCR (Invitrogen) according to the manu-
facturer’s instruction. Quantification of cDNA was performed
by using the 7300 Real Time PCR System (Applied Biosys-
tems). Activation-induced cytidine deaminase (AID) expres-
sion was quantified by using TaqMan Gene expression
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assays for AID (Mm 00507774_m1) (Applied Biosystems), while
l, c3 and c2b expression were quantified by using the sets of
specific primers in Universal Probe Library (Roche Diagnos-
tics). Primer sequences were as follows: for l sense, gata-
tatggctgaaagcttgctaa and l anti-sense, tgtgtgtctatatgtgtgcctg
a; for c3 sense, gactgtaccctccagcacct and c3 anti-sense,
actgggcttgggtattctagg; for c2b sense, ggccaagtcagaccgtca
and c2b anti-sense, aggacaggggttgattgttg. Each sample was
normalized by mouse hypoxanthine guanine phosphoribosyl
transferase (HPRT) expression (Mm 00446968_m1).
Histopathology
Kidneys were obtained from 18- to 19-week-old MRL mice,
and histological sections were stained with either periodic
acid-Schiff or hematoxylin–eosin (H&E). Glomerulonephritis
was scored on a 0–4 scale based on the intensity and extent
of histological changes. A grade 0 was given to kidneys
without glomerular lesions. The 1+ lesions corresponded to
minimal thickening of the mesangium, 2+ lesions contained
noticeable increases in both mesangial and glomerular cellu-
larity, 3+ lesions were characterized by the preceding condi-
tions with superimposed inflammatory exudates and
capsular adhesions and in 4+ lesions the glomerular archi-
tecture was obliterated in >70% of glomeruli and tubular
cast formation was extensive. Grades 3 and 4 glomerulone-
phritis were considered to be significant contributors to clini-
cal disease and/or death. Incidence of necrotizing arteritis of
small- to medium-sized muscular arteries in kidneys was
assessed by analyzing two independent sections of each
animal. The infiltration of mononuclear and/or polynuclear in-
flammatory cells in association with the destruction of the ar-
terial wall was considered positive for necrotizing arteritis.
All histological examination was controlled by a renal pathol-
ogist in a blinded manner.
Statistical analysis
Paired data were evaluated by Student’s t-test. A value of
P < 0.05 was considered statistically significant. Mortality
assessments of MRL/lpr mice and BWF1 mice were evalu-
ated by log-rank test. Incidence of renal vasculitis was eval-
uated by chi-square test.
Results
Serum IgG3 is dependent on TLR2, TLR4 and RP105/MD-1
We previously reported that RP105/ B cells were impaired
in responses to TLR2/TLR4 ligands (16). MD-1/ B cells
showed hyporesponsiveness to LPS and a TLR2/TLR1 li-
gand P3CSK4, which were indistinguishable from RP105/
B cells. The analysis of serum Igs revealed that MD-1/
mice were similar to RP105/ mice in reduced serum IgG3,
demonstrating a requirement for the RP105–MD-1 complex
in serum IgG3 production (Fig. 1A). RP105 does not have
a TLR-like signaling domain in the cytoplasmic region (13),
and RP105-mediated B cell activation was not altered in
MyD88/ mice (16, 22). Considering that serum IgG3 was
severely reduced in MyD88/ mice as well (Fig. 1A),
MyD88-dependent TLRs are likely to work in concert with
RP105/MD-1 for IgG3 production (16, 23). Given the func-
tional relationship between RP105 and TLR2/4 (16), TLR2/4
are most likely to contribute to serum IgG3 production. Mice
lacking TLR2 or TLR4 were, however, not as low as MyD88/
or RP105/ mice (16). We, therefore, suspected that TLR2
and TLR4 were redundant for IgG3 production and estab-
lished mice lacking both TLR2 and TLR4. TLR2/ TLR4/
mice were as low as MyD88/ mice in serum IgG3 (Fig.
1A). Along this line, mice lacking TIRAP, an adaptor molecule
required for signaling via TLR2 or TLR4 (24), were similar to
TLR2/TLR4/ mice in reduced serum IgG3 (T. Kobayashi,
S. Akira, K. Miyake, unpublished data). No change was ob-
served in a T-dependent isotype IgG1, whereas IgG2b was
low in mice lacking RP105 or MD-1 but not in TLR2/TLR4/
mice. IgG2c production was considerably impaired in
MyD88/ mice due to their defect in Th1 development (25).
These results clearly demonstrated that TLR2, TLR4 and
RP105/MD-1 were critically involved in basal production of
serum IgG3. Because serum IgG3 was reported to be low
in TLR7/ MRL/lpr mice (5), we also studied TLR7/
C57BL/6 mice, which showed, however, no significant alter-
ation in serum IgG3 (Fig. 1B). We also found that serum
IgG2b production was dependent on RP105/MD-1 (Fig. 1A).
Impaired expression of the c3 germ line transcript in
RP105/ and MD-1/ mice
Specific reduction in serum IgG3 and IgG2b suggested that
RP105/ or MD-1/ B cells have a defect in class switch-
ing from l to c3 or to c2b. Class switch recombination to c3
or c2b requires the germ line transcript for c3 or c2b
and AID, a master regulator of class switch recombination
(26, 27). To gain insight into a mechanism regulating serum
IgG3 and IgG2b, we first examined expression of the germ
line transcript for c3 and c2b. The germ line transcripts for
c3 or c2b, but not for c1 or c2a, were reported to be detect-
able in splenic B cells without any activation (27). It has not
been clarified whether these germ line transcripts are in-
duced autonomously or non-autonomously. The latter possi-
bility suggests that splenic B cells continuously respond to
environmental stimulation including microbial flora. Interest-
ingly, the c3 germ line transcript, which is constitutively
expressed in wild-type mice, was almost completely abol-
ished in mice lacking RP105, MD-1, MyD88 and TLR2/
TLR4/ without any significant change in mRNA for l chain
(Fig. 2A), demonstrating that the c3 transcript expression is
dependent on TLR2, TLR4 and RP105/MD-1. On the other
hand, moderate down-regulation of the c2b transcript was
observed in RP105/- or MyD88/ B cells. The changes of
the c2b germ line transcript in MD-1/ or TLR2/TLR4/
mice were much less pronounced. The c2b germ line tran-
script seemed to be differently regulated in comparison to
the c3 germ line transcript.
Constitutive TLR signaling was able to induce the c3 germ
line transcript but apparently not sufficient for AID induction,
since AID was not constitutively expressed in splenic B cells
(27). We studied AID induction in response to TLR ligands.
Enriched B cells were stimulated with LPS, P3CSK4 or CpG
for 2 days. AID mRNA was up-regulated by all the TLR
ligands examined (Fig. 2B). AID induction in B cells lacking
RP105 or MD-1 was partially impaired in response to LPS or
P3CSK4 but not at all in response to CpG. Because the c3
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germ line transcript is constitutively expressed in B cells, its
induction by LPS stimulation was much less than that of AID
(data not shown). Only ;30% increase in the c3 germ line
transcript was seen with LPS stimulation at 1 lg ml1. Simi-
lar results were reported by Muramatsu et al. (27). Constitu-
tive expression of the c3 germ line transcript is likely to be
sufficient for the class switching from l to c3.
AID induction by TLR2/4 ligands was not so severely im-
paired as compared with the c3 germ line transcript in the
steady state (Fig. 2A and B), suggesting that the impaired
induction of the c3 germ line transcript in the steady state is
principally responsible for reduced serum IgG3. These
results suggested that the constitutively expressed c3 germ
line transcript was induced by TLR2/4 and RP105/MD-1.
Given that MyD88/ and TIRAP/ mice are similar to
TLR2/TLR4/ double-deficient mice in impaired serum
IgG3 production, the TLR2/4-dependent signaling is re-
quired for serum IgG3 production. By contrast, we do not
have direct evidence for requirement of RP105 signaling in
induction of the c3 germ line transcript. It remains clarified
how RP105/MD-1 is involved in serum IgG3 production.
Roles for microbial flora in serum IgG3 production
Considering that the expression of the c3 germ line tran-
script depends on TLR2, TLR4 and RP105 in resting B cells,
B cells are likely to respond to TLR ligands without any in-
fection or immunization. Microbial flora may stimulate splenic
B cells, although spleen is not exposed to microbial flora.
Fig. 1. Serum IgG3 is dependent on TLR2, TLR4 or RP105/MD-1. (A) Levels of serum IgM, IgG1, IgG2b, IgG2c and IgG3 in indicated mice (wild-
type, RP105/, MD-1/, TLR2/TLR4/, MyD88/ mice) were determined by ELISA. The results are represented by mean values with
standard deviation (SD) from four to five mice at 7 and 11 weeks of age (except for IgG2c; measured only at 7 weeks of age). (B) The levels of
serum IgM and IgG3 in wild-type and TLR7/ mice were determined by ELISA as in (A). The results are represented by mean values with SD
from six mice at 8 weeks of age.
884 Tonic B cell activation in autoimmunity
To address a role of microbial flora, we studied germ-free
mice (Fig. 3A). Serum IgA in germ-free mice was reported
to be reduced (28). In keeping with this, serum IgA was sig-
nificantly down-regulated in the germ-free mice used in this
study, demonstrating the effectiveness of germ-free condi-
tion. Nonetheless, the rest of isotypes including IgG3 and
IgG2b was not reduced. Compared with control mice, IgM
and IgG3 were rather up-regulated. We next employed anti-
biotics treatment to deplete microbial flora. Mice were fed
with antibiotics-containing water during 4–8 weeks of age.
These mice were similar to germ-free mice in that serum
IgA was significantly reduced, confirming the reduction of
microbial flora (Fig. 3B). Despite the effective treatment with
antibiotics, serum IgG3 was not decreased at all. Instead,
IgG2b was significantly down-regulated by antibiotics treat-
ment (Fig. 3B). The exact reason for IgG2b reduction is cur-
rently unknown. These results did not necessarily negate
roles for microbial flora, but strongly suggested that micro-
bial flora is dispensable for tonic B cell activation driven by
TLR2, TLR4 and RP105/MD-1.
Roles for RP105 in serum Ig titers of lupus-prone mice
TLRs have been implicated in autoimmune diseases. Espe-
cially, in MRL/lpr mice, TLR7 was reported to deteriorate the
autoimmune disease (5). MRL/lpr mice reared in a germ-free
state were similar to those in conventional conditions with
regard to lymphoproliferation and B cell autoimmunity (29),
indicating that autoimmunity in MRL/lpr is independent of
live, non-pathogenic microbes. This report suggests that
B cells are excessively activated by non-microbial, environ-
mental stimuli in MRL/lpr mice. It is possible that such ex-
cessive B cell activation is driven not only by TLR7 but also
by TLR2, TLR4 and RP105. To address this possibility, we
established RP105/ MRL/lpr mice. We considered that
RP105/ mutation is more appropriate than TLR2/TLR4/
double mutation. The lack of RP105 impairs TLR2/4
responses only in B cells (16), whereas the lack of TLR2/4
blunts all the TLR2/4 responses not only in B cells but also
in dendritic cells, macrophages, endothelial cells or fibro-
blasts. It is difficult to discriminate the effect of TLR2/4 muta-
tion in B cells from that in non-B cells. We also introduced
RP105 deficiency into another type of lupus-prone mice,
BWF1 mice. We studied the levels of serum Igs at 20 weeks
of age and found that RP105/ MRL/lpr mice were signifi-
cantly lower than RP105+/+ MRL/lpr mice in serum IgG3 and
IgG2a. RP105/ BWF1 mice were lower than RP105+/
BWF1 mice in serum IgG3 and IgG2b (Fig. 4).
Roles for RP105 in autoimmunity in MRL/lpr
RP105/ mutation ameliorated mortality in the MRL/lpr
strain (Fig. 5A). In contrast, the lack of RP105 did not influ-
ence mortality in BWF1 mice despite IgG3 reduction
(Fig. 5A). Elevation of BUN, which correlated with renal dys-
function, was significantly improved in RP105/ MRL/lpr
mice, whereas no significant difference was detected be-
tween RP105+/ and RP105/ BWF1 mice (Fig. 5B). We fur-
ther examined glomerulonephritis in MRL/lpr mice. Despite
the improvement in BUN accumulation (Fig. 5B), any signifi-
cant change was not found in the intensity and extent of glo-
merular alterations when assessed at 18–19 weeks of age
(Fig. 5C). MRL/lpr mice spontaneously develop systemic-
necrotizing arteritis of small- and medium-sized muscular
arteries, which is characterized by the infiltration of mononu-
clear and/or polynuclear leukocytes and by the destruction
of the arterial wall (30). Notably, necrotizing arteritis in kid-
neys was observed less frequently in RP105/ MRL/lpr than
in RP105+/+ MRL/lpr (Fig. 5D). Impaired renal perfusion may
be responsible for deterioration of renal function revealed by
elevated BUN.
MRL/lpr mice develop severe splenomegaly and lymph-
adenopathy due to accumulation of lymphocytes expressing
an activated phenotype in these organs (31). The weight of
lymphoid organs including spleen, mesenteric lymph nodes
and axillary lymph nodes was examined at 19 weeks of
age. We found that splenomegaly and lymphadenopathy
were both significantly reduced in the absence of RP105 in
MRL/lpr mice (Fig. 6A and B). Due to unknown reason, axil-
lary lymph nodes were most apparent in difference between
RP105/ MRL/lpr and RP105+/+ MRL/lpr mice (Fig. 6B). We
next examined lymphocyte subpopulation in the spleen.
Decreases in the percentages of CD4+ T cells and CD8+
T cells were significantly improved, whereas no significant
difference was observed in the percentages of CD4/CD8
double-negative T cells (DNTCs) and B cells (Fig. 6C).
Fig. 2. c3 germ line transcript is dependent on TLR2, TLR4 and
RP105/MD-1. (A) Expression of mRNA encoding l (left), c3 (middle)
and c2b (right) chain in enriched splenic B cells was measured by
real-time reverse transcription (RT)–PCR. Enriched splenic B cells
were obtained from wild-type, RP105/, MD-1/, MyD88/ or
TLR2/TLR4/ mice as indicated in the figure. RT–PCR was
conducted as described in Methods. The results are represented
as mean value with standard deviation from triplicate samples. (B)
Splenic B cells from indicated mice were stimulated with LPS (1 lg
ml1), P3CSK4 (1 lg ml1) or CpG (1.0 lM) for 2 days. Quantitative
RT–PCR was conducted for measuring AID mRNA expression. Each
expression level was normalized by mouse HPRT expression. Results
are representatives of more than three independent experiments.
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RP105 deficiency seemed to decrease the total number of
DNTC without influencing the percentage of DNTC in spleen,
as revealed by ameliorated splenomegaly (Fig. 6A and B).
Activation status of splenic B cells was analyzed by cell sur-
face staining of CD44 and CD69, which did not reveal any
difference in the absence or presence of RP105 (Fig. 6D).
In contrast, CD44+/CD4+ activated T cells in mesenteric
lymph nodes were significantly decreased in the absence of
RP105 in MRL/lpr mice (Fig. 6E).
Auto-antibody production is not altered by the lack of RP105
We finally studied auto-antibody production against DNA
and chromatin. Unexpectedly, we could not find any signifi-
cant difference between RP105/ and RP105+/+ MRL/lpr
mice (Fig. 7). Kikuchi et al. (32) reported that the transgenic
mice expressing IgG3 against IgG2a RF developed necro-
tizing arteritis in small- and medium-sized arteries of the kid-
ney. We therefore determined the serum levels of IgG3 anti-
IgG2a RF by ELISA (Fig. 8). We could not find any reduction
in the IgG3 anti-IgG2a RF activity regardless of improvement
in necrotizing arteritis in RP105/ MRL/lpr mice. Although
RP105 was likely to have a pathogenic role in necrotizing
arteritis formation in the kidneys of MRL/lpr mice, IgG3
anti-IgG2a RF did not seem to be involved in the RP105-
dependent arteritis.
Discussion
The present study demonstrated that B cells are constitu-
tively activated by pathogen sensors including TLR2, TLR4
and RP105/MD-1. Continuous B cell activation leads to the
induction of the c3 germ line transcript and production of
serum IgG3. In our previous study (16), we showed that
antigen-specific, T-independent Ig production driven by
TLR2/4 ligands is all dependent on RP105. A role for
RP105/MD-1 in serum Ig production seems, however, to be
more specific for IgG3 than that in T-independent B cell
Fig. 3. Serum IgG3 is not influenced by microbial flora depletion. Sera were collected from 7-week-old ICR mice grown under specific pathogen-
free (open diamond) or germ-free condition (closed triangle) as indicated in the figure (A) or from 8-week-old BALB/c mice fed with water with
(closed triangle) or without antibiotics (open diamond) during 4–8 weeks of age (B). The levels of serum IgM, IgG3, IgG2b, IgG1 and IgA were
determined by ELISA. The results were represented as individual values and mean values shown by horizontal bars from six (A) or five (B) mice.
The experiment using germ-free mice was conducted once, whereas antibiotic treatments were independently performed three times and gave
similar results. *P < 0.05, **P < 0.01.
Fig. 4. RP105/ mutation decreased serum IgG3 in lupus-prone
mice. Sera were collected from RP105+/+ MRL/lpr (20 week old,
n = 9), RP105/MRL/lpr (20 week old, n = 10), RP105+/ BWF1 (20
week old, n = 17) or RP105/ BWF1 (20 week old, n = 17) as
indicated in the figure. The levels of serum IgG3, IgG1, IgG2b and
IgG2a were determined by ELISA. The results were represented as
mean values with standard errors.
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responses. TLR-independent mechanisms, either T depen-
dent or independent, would have an important role in serum
Ig production. In this regard, serum IgG3 production seems
to be most dependent on TLRs and least dependent on
TLR-independent mechanisms. By contrast, serum IgM and
IgG2b are likely to be influenced by TLR-independent mech-
anisms as well as by TLR-dependent mechanisms.
Although the requirement for these pathogen sensors sug-
gested a role for microbial flora in inducing serum IgG3, we
could not detect any alteration in serum IgG3 in germ-free
or antibiotics-treated mice (Fig. 3). With regard to IgG2b
production, MD-1/ mice are impaired only in serum IgG2b,
but not in the c2b germ line transcript (Figs 1A and 2A). In
this regard, MD-1/ mice were distinct from RP105/ mice,
which are impaired in both serum IgG2b and the c2b germ
line transcript (Figs 1A and 2A). The discrepancy between
MD-1/ and RP105/ mice might suggest a pleiotropic
role for soluble MD-1. IgG3 is predominantly produced in
T-independent responses, whereas IgG2b is produced in
T-dependent responses as well. In this regard, it is of note
that MD-1 was reported to have a regulatory role in T cell
responses (33). Further study is required for clarifying this
issue.
The results in Figs 1–3 together with our previous study
(16) demonstrated that TLR2, TLR4 and RP105/MD-1 have
a role in tonic B cell activation. We next asked a pathogenic
role for the RP105-dependent tonic B cell activation in auto-
immune diseases by introducing RP105/ mutation into
Fig. 5. Lack of RP105 ameliorated autoimmune disease in MRL/lpr mice but not in BWF1 mice. (A) Survival of MRL (n = 5, female), RP105+/+
MRL/lpr (n = 52, female), RP105/ MRL/lpr (n = 53, female), RP105+/ BWF1 (n = 19, female) or RP105/ BWF1 (n = 18, female) mice
were shown until 50 weeks of age. *P < 0.01 by log-rank test. (B) Sera from MRL/lpr (n = 12, 19 week old), MRL/lpr RP105/ (n = 9, 19 week old),
MRL+/+ (n = 5, 19 week old), RP105+/ BWF1 (n = 17, 20 week old) or RP105/ BWF1 (n = 17, 20 week old) mice were used for measuring BUN.
The results were represented as a mean value with standard deviation. (C) The severity of glomerulonephritis in MRL/lpr (n = 19, female),
RP105/MRL/lpr (n = 18, female) or MRL (n = 6, female) mice at 18–19 weeks of age was scored on a 0–4 scale (see Methods). Horizontal bars
denote mean values. NS, not significant. (D) The percentages of mice suffering from necrotizing arteritis in kidneys were shown in the same mice
as used in (C). ND, not detected. *P < 0.05 by chi-square test.
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autoimmune-prone mice. RP105/ mutation ameliorated
lymphoproliferation in MRL/lpr mice (Fig. 6A and B). Consid-
ering that deficiency of TLR2, TLR4, RP105 or MD-1 does
not influence the B cell differentiation (14, 18, 34, 35), the ef-
fect of RP105/ mutation on autoimmune diseases is likely
to be due to defective B cell activation in the steady state.
MRL/lpr mice reared in a germ-free condition were similar to
those in conventional conditions with regard to lymphoprolif-
eration and B cell autoimmunity (29), indicating that autoim-
munity in these mice is independent of live, non-pathogenic
microbes. Taken together with our results from wild-type
mice (Figs 1–3), B cells are likely to be activated by non-
microbial, environmental stimuli in both healthy and autoim-
mune-prone mice. Although RP105/MD-1 is expressed on
dendritic cells and macrophages as well as on B cells,
RP105/ mice showed impaired response to LPS or lipo-
peptides only in B cells but not in dendritic cells or macro-
phages (16). These results suggest that TLR2, TLR4 and
RP105/MD-1 on splenic B cells are continuously activated in
a microbial flora-independent manner not only in wild-type
mice but also in MRL/lpr mice.
What activates B cells in the steady state in MRL/lpr mice?
In MRL/lpr mice, abnormal T cells accumulate as a conse-
quence of defect in Fas-dependent apoptosis and become
a major source of necrotic cells (2). Resultant necrotic cells
were suggested to activate TLR7/9 to produce auto-antibody
(3, 5). Necrotic cells might also activate TLR2/4 and RP105/
MD-1 on B cells in healthy and autoimmune-prone mice.
Alternatively, dietary exposure may have a role for stimulat-
ing TLR2/TLR4/RP105 on B cells, since the previous report
suggested a possible role for dietary exposure in inducing
lymphoproliferation in MRL/lpr mice (29).
The lack of RP105 extended the survival of MRL/lpr mice
probably due to amelioration of overall renal function, as
documented by improvement of BUN elevation. Although
we were unable to detect any alteration in glomerulonephri-
tis, the amelioration of renal function in RP105/ MRL/lpr
would be due to the significantly lower incidence of renal-
necrotizing arteritis than in MRL/lpr mice. Systemic-necrotizing
arteritis was reported to be observed in MRL/lpr mice but
not in BWF1 mice (2), which may in part explain a reason
why renal function was ameliorated in MRL/lpr but not in
B/WF1 by the lack of RP105 (Fig. 5B). Necrotizing arteritis
was shown to be induced by IgG3 anti-IgG2a RF in MRL/lpr
(32). We, however, could not detect any difference in IgG3
anti-IgG2a RF in RP105/ MRL/lpr mice (Fig. 8). Moreover,
production of all IgG subtypes of antibodies against dsDNA
or chromatin was not changed in RP105/ MRL/lpr mice
(Fig. 7). Given that serum IgG3 and IgG2a were down-
regulated by RP105/ mutation in MRL/lpr mice, these anti-
bodies to as yet uncharacterized auto-antigens could be
responsible for renal arteritis. TLR2 and TLR4 react with
Fig. 6. The effect of RP105 deficiency in the lymphoid organs of MRL/lpr mice. RP105+/+ (white bars, n = 12, female), RP105/ (slashed bars,
n = 9, female) and healthy MRL (black bars, n = 5, female) mice were assayed for various parameters of disease activity and immune activation.
(A) Weight of mesenteric lymph nodes or spleen from mice used in (Fig. 6B) was shown. (B) Weight of axillary lymph nodes from mice used in
(Fig. 6B) was shown (graph). The results were represented as mean value with standard errors. Representative photograph of the axillary lymph
nodes from RP105+/+ or RP105/ mice is also shown. Black bar indicates 1 cm. *P < 0.05, **P < 0.01. (C–E) Lymphocyte subpopulations and
their activation status were analyzed by flow cytometry. Shown were proportions of splenic CD4+ T cells, CD8+ cells, CD4/CD8 DNTC, B cells
(C), CD44+ and CD69+ splenic B cells (D) and CD44+/CD4+ T cells in mesenteric lymph node (E).
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microbial membrane components, raising a possibility that
RP105-dependent antibodies may react with self-membrane
components such as phospholipids.
It is also possible that the pathogenic role for RP105 in
MRL/lpr mice is not directly linked with auto-antibody pro-
duction. Ameliorated renal function in RP105/ MRL/lpr
mice may be explained by a B cell-dependent but auto-
antibody-independent mechanism. When rendered B cell
deficient, MRL/lpr mice developed substantially less lymph-
adenopathy or splenomegaly and lacked glomerulonephritis,
vasculitis and skin disease (36, 37). Ab-independent roles
for B cells in autoimmune diseases were revealed by com-
paring B cell-deficient MRL/lpr mice and those lacking only
serum Igs. Survival of serum Ig-deficient MRL/lpr was be-
tween MRL/lpr and B cell-deficient MRL/lpr (38). MRL/lpr-
lacking serum Igs were ameliorated in glomerulonephritis as
much as MRL/lpr-lacking B cells, whereas no improvement
was seen in renal vasculitis, suggesting a role for B cells
per se but not for auto-antibodies in renal vasculitis. In
humans, rituximab, a humanized anti-CD20, is broadly used
for the autoimmune disease therapies to deplete autoreac-
tive B cells. Rituximab treatment in humans (39), or in trans-
genic mice expressing human CD20 (40), reduced the
disease severity but not altered auto-antibody levels, indicat-
ing that B cells play a role in autoimmune disease via their
role as antigen-presenting cells. With regard to RP105/
MRL/lpr mice, lymphadenopathy/splenomegaly and CD44+
activated T cells in mesenteric lymph nodes were apparently
decreased (Fig. 6A, B and E). Such differences in T cells
may reflect reduced activity of B cells as antigen-presenting
cells in RP105/ MRL/lpr mice.
Previous studies revealed differences between two types
of lupus-prone mice, MRL/lpr and BWF1. FccRs have been
implicated in autoimmune glomerulonephritis in BWF1 mice,
as documented by the protection of lupus nephritis in these
strains deficient in FcRc chains (41). Direct activation of cir-
culating FccR-bearing myeloid cells, including monocytes/
macrophages, by glomerular immune complex deposits is
likely to be sufficient to initiate inflammatory responses (42).
MRL/lpr mice are distinct from BWF1 mice in which the lack
of FcRc chain did not ameliorate lupus nephritis (43), imply-
ing heterogeneity of pathophysiologic basis of autoimmune
nephritis. Another difference was revealed by type I IFN. In
NZB or BWF1 mice, lupus-like disease was accelerated and
enhanced by type I IFNs themselves or their inducer. More-
over, disease was ameliorated in NZB mice lacking the type
I IFN receptor (IFNAR) (44). In contrast, the absence of
IFNAR exacerbated lupus disease of MRL/lpr mice (45).
The present study revealed another difference between
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Tonic B cell activation in autoimmunity 889
MRL/lpr and BWF1 in which the lack of RP105 ameliorated
disease progression in MRL/lpr mice but not in BWF1 mice.
These two strains may be distinct from each other in roles
for TLRs in induction of lupus nephritis. Along this line, a re-
cent report is noteworthy that the lack of TLR9 ameliorated
lupus nephritis in an autoimmune-prone mouse strain (46).
Although the autoimmune-prone mice used in this study
were distinct from BWF1, both are similar in that FccR-
dependent inflammation has a pathogenic role in lupus ne-
phritis. By contrast, TLR9 had an opposing role in MRL/lpr
in which the lack of TLR9 did not ameliorate but rather exac-
erbated lupus nephritis (5). These results suggested two dis-
tinct types of lupus nephritis, which were discriminated by
roles for FccR, IgG3 auto-antibody, RP105/MD-1, TLR2,
TLR4, TLR9 and type I IFNs.
The present study stressed that TLR2, TLR4 and RP105
continuously transduce the signal without any apparent in-
fection, indicating that these innate pathogen sensors may
continuously respond to environmental stimuli. The discrimi-
nation between infectious and steady state by TLRs is
still an important and unresolved issue in the innate immune
system.
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Abbreviations
AID activation-induced cytidine deaminase
BUN blood urea nitrogen
DNP 2,4-dinitrophenyl
DNTC double-negative T cell
HPRT hypoxanthine guanine phosphoribosyl transferase
MyD88 myeloid differentiation gene 88
P3CSK4 N-palmitoyl-S-(2,3-bis (palmitoyloxy)-(2R,S)-propyl)-
(R)-cysteinyl-seryl-(lysyl)3-lysine
RF rheumatoid factor
RP105 Radioprotective105
SLE systemic lupus erythematosus
TLR Toll-like receptor
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